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Abstract
This study explores the response to COVID-19 from investigators, editors,
and publishers and seeks to define challenges during the early stages of
the pandemic. A cross-sectional bibliometric review of COVID-19 litera-
ture was undertaken between 1 November 2019 and 24 March 2020,
along with a comparative review of Middle East respiratory syndrome
(MERS) literature. Investigator responsiveness was assessed by measuring
the volume and type of research published. Editorial responsiveness was
assessed by measuring the submission-to-acceptance time and availability
of original data. Publisher-responsiveness was assessed by measuring the
acceptance-to-publication time and the provision of open access. Three
hundred and ninety-eight of 2,835 COVID-19 and 55 of 1,513 MERS sea-
rch results were eligible. Most COVID-19 studies were clinical reports
(n = 242; 60.8%). The submission-to-acceptance [median: 5 days (IQR: 3–11)
versus 71.5 days (38–106); P < .001] and acceptance-to-publication [median:
5 days (IQR: 2–8) versus 22.5 days (4–485-; P < .001] times were strikingly
shorter for COVID-19. Almost all COVID-19 (n = 396; 99.5%) and MERS
(n = 55; 100%) studies were open-access. Data sharing was infrequent, with
original data available for 104 (26.1%) COVID-19 and 10 (18.2%) MERS stud-
ies (P = .203). The early academic response was characterized by investiga-
tors aiming to define the disease. Studies were made rapidly and openly
available. Only one-in-four were published alongside original data, which is a
key target for improvement.
Keywords: coronavirus, SARS-CoV-2, dissemination, open-access, data
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
spread rapidly since it began in the city of Wuhan in late 2019
(Xu et al., 2020). The outbreak has been declared as a pandemic
by the World Health Organization (WHO), reflecting its spread to
more than 200 countries worldwide (WHO, 2020c). As of April
2020, there have been more than 100,000 deaths and the num-
ber of those affected continues to rise (WHO, 2020a).
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In response to this unprecedented situation, healthcare sys-
tems around the world have taken urgent action to scale up med-
ical staffing, equipment, and infrastructure. In the UK, this is
demonstrated by the construction of new field hospitals, the
return of thousands of retired healthcare workers, and the re-pur-
posing of many acute and urgent hospital services (NHS
England, 2020). The role that science and data play in the face of
the COVID-19 pandemic must also be recognized. Robust and
rapidly available evidence is essential for improving the detection
and treatment of the virus as well as for reducing its transmission.
It is the responsibility of all members of the academic community
to facilitate this transfer of knowledge so that patients around
the world receive the best evidence-based care available.
There is limited information about how the academic com-
munity has responded to COVID-19 and how this can be further
guided during times of global crisis. There is a need for investiga-
tors to respond urgently to new clinical priorities across all sec-
tors of healthcare and to work in unfamiliar environments.
Journal editors must facilitate rapid and robust peer review while
making difficult editorial decisions based on little previous aca-
demic background. Publishers must mobilize quickly to enable
timely publication of manuscripts so that research outputs can be
realized and implemented into practice. An early understanding
of this response is important so that the academic community




As a review of published literature, approval by a research ethics
committee was not applicable. Since only bibliometric outcomes
were considered, rather than outcomes of direct relevance to
research participants, this review was not eligible for registration
on the PROSPERO database. There were no changes to the
research design or outcomes during the course of the study. The
results are reported with consideration to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRI-
SMA) Checklist (Liberati et al., 2009).
Aims and objectives
The study aimed to examine the responsiveness of the academic
community to COVID-19 during its early stages. The following
objectives were predefined:
• To explore investigator responsiveness by describing the vol-
ume and type of research accepted in peer-reviewed journals.
• To explore editorial responsiveness by describing the time
taken to facilitate editorial/peer review and the availability of
original data as a condition of publication.
• To explore publisher responsiveness by describing the time
taken for accepted manuscripts to be available and the provi-
sion of open-access publication.
Study design
This was a systematic, cross-sectional, bibliometric review of exis-
ting healthcare literature related to COVID-19. To facilitate com-
parisons of outcomes in a unique setting, a comparable review of
Middle East respiratory syndrome (MERS) was also performed
and used as control. MERS was chosen as a suitable comparator
because it similarly represents a respiratory illness caused by a
zoonotic coronavirus, but was not classified as a pandemic or a
Public Health Emergency of International Concern by the WHO
during the search period (WHO, 2020d). It therefore represents a
non-COVID-19 and non-pandemic control.
Definitions
In line with the WHO, COVID-19 describes the disease caused
by the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and MERS describes the disease caused by the Middle
East respiratory syndrome-related coronavirus (MERS-CoV)
(WHO, 2020b). The early stages of COVID-19 was defined as the
period between the first known human case and its classification
as a pandemic on 11 March 2020 (WHO, 2020c). Availability of
original data was considered to be an editorial responsibility since
this is recommended by the International Committee of Medical
Journal Editors for clinical trials and can be enforced as a condi-
tion of publication (Taichman et al., 2017). Open-access was
defined by the model of Gold open-access, where articles and
related content are freely accessible at the point of publication.
Fully open-access journals were defined by their listing on the
Directory of Open Access Journals (https://doaj.org).
Key points
• COVID-19 publications show rapid response from investi-
gators, specifically aiming to define the disease.
• Median time between submission and acceptance of
COVID-19 articles is 5 days demonstrating rapid decision-
making compared with the median of 71.5 days for MERS
articles.
• Median time from acceptance to publication of COVID-19
articles is 5 days, confirming the ability to introduce rapid
increases at times of crisis, such as during the SARS
outbreak.
• The majority of both COVID-19 and MERS articles are
available open-access.
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Search strategy
Systematic searches of MEDLINE (via OvidSP) and EMBASE (via
OvidSP) were performed by a single investigator on 25 March
2020. For COVID-19, time limits were set between 1 November
2019 and 24 March 2020. This start date was chosen to repre-
sent the earliest plausible time of the first human report. The end
date reflected the official WHO classification of COVID-19 as a
global pandemic (11 March 2020) along with a 14-day lag period
for manuscripts already in production. For MERS, a comparable
search was performed between 1 November 2018 and 24 March
2019. The difference in year was chosen to represent a non-
COVID-19 control period. The results of both searches were first
de-duplicated and saved offline. Two independent investigators
then screened titles, abstracts, and full texts for possible inclu-
sion, with discrepancies addressed through re-examination and
discussion. A full outline of search strategies is available in
Table 1.
Study eligibility criteria
For published studies, any COVID-19- or MERS-related manu-
script available online or in print within the defined time periods
was eligible for inclusion. Eligible studies had to report primary
data. This included studies that performed analyses using open
source data sets, but not studies that reported systematic reviews
or meta-analyses. Studies of animals or pre-clinical models were
eligible, but only if the outcomes contributed to human rather
than veterinary medicine. Articles published in non-English lan-
guages and other grey literature (such as conference abstracts)
were excluded since these are not practically accessible by the
global academic community.
Study outcomes
Academic responsiveness was considered across three groups of
the academic community. Investigator responsiveness was
explored by measuring the volume and type of research (pre-clini-
cal, clinical, and modelling) published in peer-reviewed journals.
Editorial responsiveness was explored by measuring the time
taken for editorial/peer review, defined as the number of days
between manuscript submission and acceptance. The availability
of original data to support the results was also explored. Data
were considered available if individual observations (or source
code in the case of modelling studies) were provided as a supple-
mentary file, in a controlled-access repository, or if an explicit
statement of availability from authors was present. Where the
status of data sharing was unclear, corresponding authors were
contacted and non-responses were considered to represent an
absence of data. Publisher responsiveness was explored by mea-
suring the time taken for manuscripts to complete production,
defined as the number of days between acceptance and first
availability online or in print. Publisher responsiveness was also
assessed by exploring the incidence of open-access publication.
Data collection
Data were collected by a single investigator and checked by an
independent investigator for accuracy. Data sources included full-
text manuscripts and editorial-related content. Data points of
interest were country of origin (according to the corresponding
institution), manuscript format (short communication/letter or
full-text), journal subject category, and subject category ranking
(according to Thomas Reuters Journal Citation Reports). For clini-
cal studies, additional data of interest were population (adults,
children, pregnant adults, or healthcare workers), study design
(case report, case series, observational, or interventional) and clin-
ical focus (definition of disease, diagnosis/screening, treatment,
prevention, or resource use). Definition of disease related to
studies describing clinical features and outcomes.
Statistical analysis
Data are presented descriptively using averages and measures of
variance. Continuous data were analysed using the student’s t-
test or analysis of variance (ANOVA). Categorical data were
analysed using χ2 or Fisher’s exact test. All statistical comparisons
of COVID-19 and MERS studies were pre-planned. A single sub-
analysis of data sharing practices was performed with the exclu-
sion of case reports since these may or may not provide the full
Table 1 COVID 19 and MERS search strategies (via OvidSP)







6 Severe acute respiratory syndrome coronavirus 2
7 1 OR 2 OR 3 OR 4 OR 5 OR 6
8 (Remove duplicates)
9 (Time limit: 2019–current)




3 Middle East respiratory syndrome
4 1 OR 2 OR 3
5 (Time limit: 2018–2019)
6 (Limit to English)
7 (Remove duplicates)
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complement of data within the reported manuscript. The level of
statistical significance was set at P < .05.
Assessment of quality
Since wide heterogeneity in study design was expected, a sys-
tematic assessment of study quality was not feasible. Instead,
compliance to reporting guidelines, as recommended by the
Equator Network, was used as a broad, surrogate marker of man-
uscript reporting quality. Author declarations of compliance to
the STROBE and CONSORT checklists (or other relevant check-
lists/extensions) were evaluated for all full-text observational and




Across both searches, 398 of 2,835 COVID-19 search results and
55 of 1,513 MERS search results were eligible for inclusion
(Figs. 1 and 2). Lists of all included studies are available in Appen-
dices S1 and S2 (Supporting Information). The majority of
COVID-19 studies were authored from institutions in China
(n = 254; 63.8%) whereas the majority of MERS studies were
authored from the USA (n = 14; 25.5%). A greater proportion of
COVID-19 studies were published as letters or short communica-
tions (n = 158; 39.7%) compared with MERS (n = 4; 7.3%). Infec-
tious Diseases (n = 117; 29.4%) and General and Internal
Medicine (n = 78; 19.6%) were the most common journal subject
categories for COVID-19, with the majority (n = 248; 62.3%) of
manuscripts published in the first quartile of category-specific
rankings. In contrast, the most common category for MERS stud-
ies was Virology (n = 15; 27.3%) (Table 2).
Investigator responsiveness
The first eligible COVID-19 study was reported on 21 January
2020. The volume of reports increased rapidly during the early
stages of the disease, with 23 published in January 2020 (5.8%),
169 in February 2020 (n = 42.5%), and 206 in March 2020
(51.8%). This compared with a median of nine MERS studies per
month (range: 5–20) published during the control period (Fig. 3).
The majority of COVID-19 studies were clinical (n = 242; 60.8%),
followed by pre-clinical (n = 90; 22.6%), and modelling studies
(n = 62; 15.6%). Case reports (n = 65; 26.9%) and case series
(n = 105; 43.4%) were the predominant designs for clinical stud-
ies and most of these set out to define the disease (n = 126;
52.1%). Almost all clinical studies explored general adult
populations (n = 209; 86.4%), with a handful exploring other
groups, including children (n = 16; 6.6%), pregnant adults (n = 7;
2.9%), and healthcare workers (n = 10; 4.1%) (Table 3). In con-
trast, MERS studies were mostly pre-clinical (n = 37; 67.3%),
followed by clinical (n = 13; 23.6%), modelling (n = 1; 1.8%), and
other miscellaneous (n = 3; 5.5%). MERS clinical studies mainly
comprised of case series and observational designs (both n = 5;
38.5%) and most set out to define the disease or explore issues
of diagnosis/screening (both n = 5; 38.5%). The majority explored
general adult populations (n = 11, 84.6%).
Figure 1 Flow diagram showing selection of eligible articles relating to COVID-19.
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Figure 2 Flow diagram showing selection of eligible articles relating to MERS.
Table 2 Bibliometric characteristics of COVID-19 and MERS published studies
COVID-19 (n = 398) MERS (n = 55)
Country of publicationa China 254 (63.8%) 7 (12.7%)
USA 28 (7.0%) 14 (25.5%)
Japan 13 (3.3%) 2 (3.6%)
Korea 11 (2.8%) 12 (21.8%)
Singapore 10 (2.5%) 0 (0.0%)
Canada 9 (2.3%) 1 (1.8%)
Italy 9 (2.3%) 0 (0.0%)
Germany 8 (2.0%) 4 (7.3%)
UK 8 (2.0%) 0 (0.0%)
Saudi Arabia 1 (0.3%) 8 (12.7%)
Othersb 47 (11.8%) 7 (14.5%)
Format of publication Letter/communication 158 (39.7%) 4 (7.3%)
Full-text manuscript 240 (60.3%) 51 (92.7%)
Type of research Pre-clinical 90 (22.6%) 38 (69.1%)
Clinical 242 (60.8%) 13 (23.6%)
Modelling 62 (15.6%) 1 (1.8%)
Other/miscellaneousc 4 (1.0%) 3 (5.5%)
Journal categoryd Infectious diseases 117 (29.4%) 10 (18.2%)
Medicine, general and Internal 78 (19.6%) 1 (1.8%)
Radiology, nuclear medicine, and medical imaging 44 (11.1%) 0 (0.0%)
5Academic response to COVID-19
Learned Publishing 2020 © 2020 The Author(s).
Learned Publishing published by John Wiley & Sons Ltd on behalf of ALPSP.
www.learned-publishing.org
Editorial responsiveness
The time taken for editorial and peer review was available for
257 (64.6%) COVID-19 studies and 52 (94.5%) MERS studies.
The median time from submission to acceptance was much
shorter for COVID-19 studies [median: 5 days; interquartile range
(IQR): 3–11] compared with MERS (median: 71.5 days; IQR: 38–
Table 2 Continued
COVID-19 (n = 398) MERS (n = 55)
Virology 39 (9.8%) 15 (27.3%)
Microbiology 16 (4.0%) 6 (10.9%)
Multidisciplinary sciences 8 (2.0%) 3 (5.5%)
Otherse 96 (24.1%) 20 (36.4%)
Journal category quartilef First 248 (62.3%) 20 (36.4%)
Second 50 (12.6%) 19 (34.5%)
Third 79 (19.8%) 4 (7.3%)
Fourth 5 (1.3%) 4 (7.3%)
Unclassified 16 (4.0%) 8 (14.5%)
aDetermined according to the corresponding institution.
b All others n < 6 including: Australia, Belgium, Egypt, France, Greece, Hong Kong, Hungary, India, Mexico, Nepal, the Netherlands, New
Zealand, Pakistan, Spain, Sweden, Switzerland, Taiwan, Thailand, and Vietnam.
c All miscellaneous studies were surveys.
d According to Thomas Reuters Journal Citation Reports.
e All others n < 8 including: Anesthiology; Biochemical Research Methods; Biochemistry & Molecular Biology; Biology; Cell Biology; Chem-
istry, Medicinal; Chemistry, Analytical; Critical Care Medicine; Dentistry, Oral Surgery & Medicine; Dermatology; Electrochemistry; Envi-
ronmental Sciences; Gastroenterology & Hepatology; Genetics & Heredity; Hematology; Immunology; Medical Laboratory Technology;
Medicine, Research & Experimental; Neurosciences; Oncology; Pediatrics; Pharmacology & Pharmacy; Psychiatry; Public, Environmental &
Occupational Health; Respiratory System; Surgery; unclassified.
f Ranking according to category-specific Impact Factor.
Figure 3 Volume of COVID-19 and MERS studies by month of publication.
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106) (P < .001) (Table 4). The median time for COVID-19 short
communications was shorter than for full texts (4 days, IQR: 2–
7.5 vs. 6 days, IQR 3–13; P < .001), whereas no significant differ-
ence in time was found between study designs (case report: 4.5,
IQR 2–10 vs. case series: 5, IQR 225–10 vs. observational: 6,
IQR 3–13; P = .645). Original data were available via a supple-
ment, data repository, or through direct request from the study
authors for 104 (26.1%) COVID-19 studies compared with 10
(18.2%) MERS (P = .203). When case reports were excluded, data
were available for 95 of 333 (28.5%) COVID-19 studies and 10
out of 54 (18.5%) MERS studies.
Publisher responsiveness
The time taken for production processes was available for 280
(70.4%) COVID-19 and 52 (94.5%) MERS studies. The median
time from acceptance to first publication was significantly shorter
for COVID-19 (5 days, IQR: 2–8) compared with MERS
(22.5 days, IQR: 4–485; P = .001). There was no significant dif-
ference in the time for production between letters/short commu-
nications (median: 5, IQR: 1.5–8) and full texts (median: 5, IQR:
2–8) (P = .617). Neither was there a significant difference in pro-
duction time between study designs (case report: 5, IQR: 3–8 vs.
Table 3 Characteristics of clinical COVID-19 and MERS studies
COVID-19 published (n = 242) MERS published (n = 13)
Study population Adults 209 (86.4%) 11 (84.6%)
Children 16 (6.6%) 0 (0.0%)
Pregnant adults 7 (2.9%) 0 (0.0%)
Healthcare workers 10 (4.1%) 2 (15.4%)
Study design Case report 65 (26.9%) 1 (7.7%)
Case series 105 (43.4%) 5 (38.5%)
Observational 64 (26.4%) 5 (38.5%)
Interventional 5 (2.1%) 2 (15.4%)
Novel conjunctival secretion RT-PCR test –
Novel rapid IgM–IgG antibody test –
Ribavirin, interferon-alpha –
lopinavir/ritonavir –
Oxygenation-assisted tracheal intubation –
Lopinavir/ritonavir –
Other 3 (1.2%) 0 (0.0%)
Study focus Definition of disease 126 (52.1%) 5 (38.5%)
Diagnosis/screening 81 (33.5%) 5 (38.5%)
Prevention 15 (6.2%) 0 (0.0%)
Treatment 13 (5.4%) 3 (23.1%)
Resource use 1 (0.4%) 0 (0.0%)
Other miscellaneous 6 (2.5%) 0 (0.0%)
RT-PCR, real-time reverse transcription polymerase chain reaction.
Table 4 Editorial and publisher responsiveness
COVID-19 MERS
Time to acceptancea Median 5 days 71.5 days
Interquartile range 3–11 38–106
Time to publicationb Median 5 days 22.5 days
Interquartile range 2–8 4–48.5
a Time from submission to acceptance.
b Time from acceptance to publication.
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case series: 5, IQR 2–8 vs. observational: 5, IQR: 3–775)
(P = 0.954). A total of 396 (99.5%) COVID-19 manuscripts were
available with open-access, including 275 (69.4%) manuscripts
published in hybrid journals (open-access not mandated). Unex-
pectedly, all 55 (100%) MERS manuscripts were also available
with open-access, including 26 (47.3%) manuscripts published in
hybrid journals. The difference in open-access between the two
diseases was not significant (P = 1.000).
Assessment of quality
An assessment of self-declared compliance to reporting guide-
lines was performed for 48 full-text COVID-19 studies (n = 45
observational; n = 3 interventional) and 6 full-text MERS studies
(n = 4 observational; n = 2 interventional). None of these studies
declared compliance to relevant reporting checklists, as rec-
ommended by the Equator Network.
DISCUSSION
The results demonstrate a rapid academic response to COVID-19
during its early stages. Investigators responded with reports of
cases and case series, many of which were published in major
general medical journals. The volume of interventional studies
exploring treatments was low, but this is expected to change as
on-going trials reach completion. The editorial and production
times for COVID-19 studies were strikingly shorter than MERS
controls and almost all manuscripts were openly accessible at the
point of publication. In contrast, only one-in-four COVID-19
manuscripts were published with original data available to sup-
port the results.
This study raises important considerations for the dissemina-
tion of data during the COVID-19 pandemic. First, the urgency to
produce evidence and the need for rigorous peer review must be
balanced to ensure quality of published outputs. In this study, an
absence of self-declared compliance to reporting checklists (such
as STROBE and CONSORT) may indicate a relaxation of reporting
standards. The average time to manuscript acceptance of 5 days
may also suggest a pattern of internal editorial review, rather
than review by externally invited subject-matter experts. It is not
possible to explore this with certainty from the present data
because details of peer review are not usually available. While
there is an urgent need to report outputs quickly, other routes
for provisional dissemination (such as pre-prints) may be impor-
tant to protect the robustness of peer review. Second, open-
access publication is essential so that the global medical commu-
nity can learn freely from each other. In this study, almost all arti-
cles were available with open-access for both COVID-19 and
MERS research. It is likely that this represents an extended effort
by publishers to share knowledge, since only 45% of the scholarly
literature in 2015 was published with open-access (Piwowar et
al., 2018). Consideration is needed to how this approach can be
sustained as the pandemic progresses through its recovery and
subsequent outbreak phases. Finally, this study provides an early
insight into the challenges of data sharing during the COVID-19
crisis. As more potentially practice-changing studies emerge, data
sharing will be critical for allowing scrutiny of results, reducing
unnecessary duplication, and enabling rigorous pooled analyses.
Awareness of secure access data repositories as well as guide-
lines for data stewardship will be important (Wilkinson et
al., 2016).
The academic response during times of global disease has been
explored previously. In a bibliometric analysis of the 2003 severe
acute respiratory syndrome (SARS) crisis, the difference in median
submission-to-acceptance intervals between SARS and non-SARS
articles was 106.5 days (95% CI 55.0–140.1) and the difference in
median acceptance-to-publication intervals was 63.5 days (18.0–
94.1) (Xing, Hejblum, Leung, & Valleron, 2010). Interestingly, the
median time to acceptance (55 days) and publication (77.5 days) of
SARS articles was much longer than the corresponding times of
COVID-19 research in the present study. It is possible that this
reflects a longer period of study inclusion, spanning both active and
non-active outbreak phases. In another bibliometric review of the
West African Ebola Virus Disease (EVD), the academic response was
shown to be organized around a small number of individuals with
extensive global networks. This demonstrated the role and impor-
tance of strategic planning through international cooperation and
expertise (Hagel, Weidemann, Gauch, Edwards, & Tinnemann, 2017).
More recently, two analyses of COVID-19 research found that most
data were generated from China and called for increased academic
output, particularly in the form of interventional trials of new treat-
ments (Chahrour et al., 2020; Lou et al., 2020). As shown by the pre-
vious response to EVD and the current data, it is clear this must be
done with global coordination and with a common research agenda
(COVID-19 Clinical Research Coalition, 2020).
Strengths of this study are recognized. This review provides
timely and critical information about how the academic commu-
nity have responded to this global emergency during its early
stages. Specifically, it identifies on-going challenges that must be
considered, such as the balance between rapid and robust review,
as well as the availability of original data to support published
results. Weaknesses are also recognized. This review provides an
incomplete representation of the entire research pathway. While
investigators, editors, and publishers are essential for generating
and disseminating research, other groups such as funding bodies,
research ethics committees, regulatory agencies, and patient/
stakeholder groups also play important roles. Measuring the
response of these groups is challenging since it relies on data that
are not openly available or straight forward to measure. Another
weakness is the focus on peer-reviewed publications. It is likely
that a wider body of unpublished data exist following rejection or
through investigators making results available on non-peer-
reviewed platforms such as pre-print servers. These are important
and further work to confirm their rigour and stability (i.e. changes
made during parallel submission and peer review) is needed.
There is no question that the academic response to COVID-19
from investigators, editors, and publishers has been prompt. Data
sharing is an early challenge and a commitment to this from all
members of the academic community is required. Consideration to
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how high-quality peer review can be upheld in the face of great
pressure to disseminate data must also be considered. As the pan-
demic develops, it is likely that the anatomy of COVID-19 research
will shift from efforts to describe the disease towards efforts to
treat and prevent it. Further auditing of the academic response will
be important so that the academic community can identify and
address new challenges as they emerge.
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